Yet another drug maker has agreed in principle to pay a stiff fine to resolve an investigation into its relationships with patient charities. The latest company to do so is the U.S. subsidiary of Lundbeck (HLUYY), a Danish drug maker that will fork over $52.6 million.
The announcement comes two years after the U.S. Attorney issued a subpoena in connection with an investigation of payments that Lundbeck made to an unspecified number of charities that provided financial assistance to patients taking various medicines (see page 50).
In a very brief statement, the company noted the final terms of the agreement are “subject to further negotiation with the Department of Justice.” A department spokesman declined to comment. The feds, by the way, have also been looking at sales and marketing practices involving two specific Lundbeck drugs: the Northera treatment for orthostatic hypotension and the Xenazine movement disorder pill.